Product Description
Mechanisms of Action: CB1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Obesity|Overweight|Type 2 Diabetes
Phase 2: Urinary Incontinence|Overactive Bladder|Obesity|Tobacco Use Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Taranabant: 1-Yr Weight Loss Followed by 1-Yr Prevention of Weight Regain with 1-Year Extension | P3 |
Terminated |
Obesity |
2008-10-02 |
|
| A Weight Maintenance Study of MK-0364 PN012 with 1-year Extension | P3 |
Terminated |
Obesity |
2008-10-02 |
|
| NCT00131391 | P3 |
Terminated |
Obesity |
2008-02-01 |
|
| NCT00420589 | P3 |
Terminated |
Obesity |
2008-02-01 |